TY - JOUR
T1 - Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1
AU - Moore, Andrew
AU - Shindikar, Amol
AU - Fomison-Nurse, Ingrid
AU - Riu, Federica
AU - Munasinghe, Pujika E.
AU - Parshu Ram, Thrishila
AU - Saxena, Pankaj
AU - Coffey, Sean
AU - Bunton, Richard W.
AU - Galvin, Ivor F.
AU - Williams, Michael J A
AU - Emanueli, Costanza
AU - Madeddu, Paolo
AU - Katare, Rajesh
PY - 2014/4/1
Y1 - 2014/4/1
N2 - Background: Diabetic women are five times more likely to develop congestive heart failure compared with two fold for men. The underlying mechanism for this gender difference is not known. Here we investigate the molecular mechanisms responsible for this female disadvantage and attempt safeguarding cardiomyocytes viability and function through restoration of pro-survival Pim-1.Methods and Results: Diabetes was induced by injection of streptozotocin in CD1 mice of both genders. Functional and dimensional parameters measurement using echocardiography revealed diastolic dysfunction in female diabetic mice within 8 weeks after STZ-induced diabetes. This was associated with significant downregulation of pro-survival Pim-1 and upregulation of pro-apoptotic Caspase-3, microRNA-1 and microRNA-208a. Male diabetic mice did not show any significant changes at this time point (P <0.05 vs. female diabetic). Further, the onset of ventricular remodelling was quicker in female diabetic mice showing marked left ventricular dilation, reduced ejection fraction and poor contractility (P <0.05 vs. male diabetic at 12 and 16 weeks of STZ-induced diabetes). Molecular analysis of samples from human diabetic hearts confirmed the results of pre-clinical studies, showing marked downregulation of Pim-1 in the female diabetic heart (P <0.05 vs. male diabetic). Finally, in vitro restoration of Pim-1 reversed the female disadvantage in diabetic cardiomyocytes.Conclusions: We provide novel insights into the molecular mechanisms behind the rapid onset of cardiomyopathy in female diabetics. These results suggest the requirement for the development of gender-specific treatments for diabetic cardiomyopathy.
AB - Background: Diabetic women are five times more likely to develop congestive heart failure compared with two fold for men. The underlying mechanism for this gender difference is not known. Here we investigate the molecular mechanisms responsible for this female disadvantage and attempt safeguarding cardiomyocytes viability and function through restoration of pro-survival Pim-1.Methods and Results: Diabetes was induced by injection of streptozotocin in CD1 mice of both genders. Functional and dimensional parameters measurement using echocardiography revealed diastolic dysfunction in female diabetic mice within 8 weeks after STZ-induced diabetes. This was associated with significant downregulation of pro-survival Pim-1 and upregulation of pro-apoptotic Caspase-3, microRNA-1 and microRNA-208a. Male diabetic mice did not show any significant changes at this time point (P <0.05 vs. female diabetic). Further, the onset of ventricular remodelling was quicker in female diabetic mice showing marked left ventricular dilation, reduced ejection fraction and poor contractility (P <0.05 vs. male diabetic at 12 and 16 weeks of STZ-induced diabetes). Molecular analysis of samples from human diabetic hearts confirmed the results of pre-clinical studies, showing marked downregulation of Pim-1 in the female diabetic heart (P <0.05 vs. male diabetic). Finally, in vitro restoration of Pim-1 reversed the female disadvantage in diabetic cardiomyocytes.Conclusions: We provide novel insights into the molecular mechanisms behind the rapid onset of cardiomyopathy in female diabetics. These results suggest the requirement for the development of gender-specific treatments for diabetic cardiomyopathy.
KW - Apoptosis
KW - Cardiac dysfunction
KW - Cardiomyopathy
KW - Diabetes
KW - Gender difference
UR - http://www.scopus.com/inward/record.url?scp=84903477868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903477868&partnerID=8YFLogxK
U2 - 10.1186/1475-2840-13-68
DO - 10.1186/1475-2840-13-68
M3 - Article
C2 - 24685144
AN - SCOPUS:84903477868
SN - 1475-2840
VL - 13
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 68
ER -